She did state in a presentation that combinations will be even better. She wasn't throwing shade on DCVax but the work they have been doing with DCVax and adjuvants are extending life even longer for patients. Testing going on now are with adjuvants. GBM patients getting DCVax plus an agonist get 50% survival rates from recent tests.
Market Data 
Markets 
AI
